Table 2 Adverse events reported by two or more healthy adult participants after repeated oral dosing of a range of PF-06427878 doses in humans (studies B7871002 and B7871005).

Adverse events reported by two or more healthy adult participants after repeated oral dosing of a range of PF-06427878 doses in humans (studies B7871002 and B7871005)..

Placebo*PF-06427878 dose per day (administration divided Q8H with a meal)
15 mg45 mg150 mg450 mg1500 mg
Number of
participants per
group
20688912
BMI, kg/m2, median
(range)
31.0 (24.6–44.7)26.1 (24.0–27.6)24.8 (21.4–30.2)26.8 (23.6–35.1)27.6 (25.5–31.5)33.8 (27.1–40.2)
Number of healthy adult participants with specific adverse events
Diarrhea201020
Abdominal pain201100
Headache201100
Dyspepsia200100
Nasal dryness102000
Constipation010011
Flatulence002000
Gastroenteritis100010

*Combining participants randomized to placebo in study B7871002 (n = 8) and B7871005 (n = 12).

†Adverse event of moderate intensity; all other adverse events were mild in intensity.